Overall, fluctuating symptom control was the most commonly cited reason for discontinuing a prior therapy, identified by 57% of providers, while preference for a consistent treatment schedule was the ...

Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...

Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...

Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a ...

Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...

With two on-label agents now available, the panel turns to what actually drives the choice between them, noting how recently ...

The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...

SHIELD randomizes ~150 adults (18–65 years) to placebo-controlled evaluation of valacyclovir/celecoxib with an added 25-day ...

Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...

The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...